Start of Phase I/II Gene Therapy Clinical Trial for Hemophilia B (redOrbit)

March 10th, 2010 by admin

AMSTERDAM, March 10, 2010 /PRNewswire-FirstCall/ — Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today that the first patient has been dosed in the Phase I/II exploratory clinical trial with a gene therapy product for hemophilia B, a seriously debilitating and potentially lethal disease. The trial is an open label dose-escalation study …

This entry was posted on Wednesday, March 10th, 2010 at 1:12 pm and is filed under Gene Therapy, Genetic Therapy, Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

Comments are closed.